UK Investor Magazine – Top Stock Picks for 2022 with Alan Green

investor

  Alan Green joins the UK Investor Magazine Podcast to deliver his top stock picks for 2022. We touch briefly on the economic outlook for 2022 before delving into the companies Alan will be keeping a particularly close eye on next year. Top picks for 2022: Technology Minerals #TM1 Power Metal Resources #POW Blue Star […]

Poolbeg Pharma #POLB – Drug Discovery

  Artificial Intelligence can play an exciting role in Infectious Disease drug discovery. Learn more about how #AI can deliver transformational data analysis in our recent article in @Pharmafocus , written by Liam Tremble, PhD Project Manager, R&D Operations https://bit.ly/31UZFbz

Poolbeg Pharma #POLB – agrees option agreement with UCD

polb irish times

#POLB featured in the Irish Times following the recently announced Option Agreement to licence #MelioVac with University College Dublin Potential to generate significant returns for investors Contributing to the global response to the threat of infectious diseases https://www.irishtimes.com/business/health-pharma/poolbeg-pharma-agrees-option-agreement-with-ucd-1.4747770

Poolbeg Pharma #POLB – Exec Chairman Cathal Friel & CEO Jeremy Skillington talk to Alan Green

Poolbeg Pharma #POLB Exec Chairman Cathal Friel and CEO Jeremy Skillington talk to Alan Green about the company’s ‘capital light’ business model. We discuss the POLB 001 asset, spun out of Open Orphan #ORPH, data samples, the PredictViral and vaccine discovery platforms plus further pipeline products. Cathal discusses the company cash position, and Jeremy highlights […]

#POLB Poolbeg Pharma – PredictViral™ Patent update

4 October 2021 – Poolbeg Pharma (AIM: POLB), ‘Poolbeg’ or the ‘Company’, a clinical stage infectious disease pharmaceutical company with a capital light clinical model, provides an update on new patent filings for its PredictViral™ platform that estimates disease severity and contagiousness in people who are recently infected with a respiratory virus. Expanding on existing […]

Poolbeg Pharma #POLB – RNA sequencing ahead of AI analysis programme

polb

RNA sequencing ahead of pioneering AI analysis programme 7 October 2021 – Poolbeg Pharma (AIM: POLB), Poolbeg’ or the ‘Company’, a clinical stage infectious disease pharmaceutical company with a capital light clinical model, has partnered with leading global biopharma services company, Eurofins Genomics (‘Eurofins’), to complete RNA sequencing for Poolbeg of Respiratory Syncytial Virus (RSV) […]

Open Orphan #ORPH – Major year-on-year revenue growth and profitable H1 2021 performance following a year of turnaround and transition in 2020

Open Orphan (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and a world leader in vaccine and antiviral testing using human challenge clinical trials, announces its unaudited interim results for the six months ended 30 June 2021. These results show a continued pattern of profitability from Q4 2020 to a firmly profitable position […]

Poolbeg Pharma #POLB – Admission to AIM and First day of trading

Poolbeg Pharma (AIM: POLB), a clinical stage infectious disease pharmaceutical company with a capital light clinical model , is pleased to announce that admission of its entire issued share capital to trading on the AIM market of the London Stock Exchange will become effective and dealings will commence at 8.00 a.m. today under the ticker […]